Radiopharmeaceuticals

Radiopharmaceuticals are drugs that contain radioactive materials, known as radioisotopes. These drugs may be administered by multiple routes and travel to the body to treat cancer or to reduce symptoms. Radiopharmaceuticals release radiation (alpha and beta particles) that target the affected areas.
 
Everyone responds to radiopharmaceuticals differently. Talk to your doctor or pharmacist about what to expect, including any side-effects you may experience while on these medications. Some therapies used to treat prostate cancer may interact with other prescription or non-prescription medications you are taking. Tell your doctor or pharmacist if you are taking any medications.
 
Below is a list of common radiopharmaceuticals used to treat prostate cancer. Click on each drug name for further information including:
 
  • what the drug is and how it works
  • how the drug is administered
  • possible side effects of the drug
  • whether the drug is covered by your provincial drug program

Radium 223 Dichloride (Xofigo)
 




 




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More

Prostate Cancer Canada announces new President and CEO

Toronto, December 21, 2017 – After five successful years under the leadership and guidance of outgoing President and CEO, Rocco Rossi, Prostate Cancer Canada (PCC) is excited to announce the appointment of a most worthy successor in Peter Coleridge, past national CEO of the Canadian Mental Health Association and current national President and CEO of Big Brothers Big Sisters of Canada.
More

Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More


Click here for news archive